We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced that it is ending the development of the cancer program called tusamitamab ravtansine based on the outcome of a prespecified interim analysis conducted by an Independent Data Monitoring Committee (IDMC).
The CARMEN-LC03 study investigated tusamitamab ravtansine, a type of an antibody-drug conjugate, as a monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous non-small cell lung cancer whose tumors express high levels of carcinoembryonic antigen-related cell adhesion molecule 5.
The CARMEN-LC03 study had dual primary endpoints – progression-free survival (PFS) and overall survival (OS).
Shares of Sanofi have inched up 0.9% in the past year compared with the industry’s increase of 4.2%.
Image Source: Zacks Investment Research
Per the finding of IDMC, tusamitamab ravtansine failed to meet the dual primary endpoint of improving PFS versus docetaxel in the CARMEN-LC03 study.
Although treatment with tusamitamab ravtansine demonstrated an improved OS trend, Sanofi decided to stop further clinical development of tusamitamab ravtansine based on non-improvement in PFS in the final analysis.
Despite the study data falling short of expectations, management will continue to explore the potential of tusamitamab-based antibody drug conjugates in several other types of cancer indications.
Antibody drug conjugates are being considered a disruptive innovation in the pharmaceutical industry as these allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
In the past 60 days, estimates for Taro Pharmaceutical’s 2024 earnings per share have improved from 96 cents to $1.10. In the past year, shares of TARO have surged 41.2%.
Earnings of Taro Pharmaceutical beat estimates in two of the last four quarters while missing the same on the remaining two occasions. TARO delivered a four-quarter earnings surprise of 10.06%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have decreased 0.7%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 64 cents. In the past year, shares of PBYI have lost 4.1%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
Sanofi (SNY - Free Report) announced that it is ending the development of the cancer program called tusamitamab ravtansine based on the outcome of a prespecified interim analysis conducted by an Independent Data Monitoring Committee (IDMC).
The CARMEN-LC03 study investigated tusamitamab ravtansine, a type of an antibody-drug conjugate, as a monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous non-small cell lung cancer whose tumors express high levels of carcinoembryonic antigen-related cell adhesion molecule 5.
The CARMEN-LC03 study had dual primary endpoints – progression-free survival (PFS) and overall survival (OS).
Shares of Sanofi have inched up 0.9% in the past year compared with the industry’s increase of 4.2%.
Per the finding of IDMC, tusamitamab ravtansine failed to meet the dual primary endpoint of improving PFS versus docetaxel in the CARMEN-LC03 study.
Although treatment with tusamitamab ravtansine demonstrated an improved OS trend, Sanofi decided to stop further clinical development of tusamitamab ravtansine based on non-improvement in PFS in the final analysis.
Despite the study data falling short of expectations, management will continue to explore the potential of tusamitamab-based antibody drug conjugates in several other types of cancer indications.
Antibody drug conjugates are being considered a disruptive innovation in the pharmaceutical industry as these allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Taro Pharmaceutical Industries Ltd. (TARO - Free Report) , Entrada Therapeutics, Inc. (TRDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Taro Pharmaceutical’s 2024 earnings per share have improved from 96 cents to $1.10. In the past year, shares of TARO have surged 41.2%.
Earnings of Taro Pharmaceutical beat estimates in two of the last four quarters while missing the same on the remaining two occasions. TARO delivered a four-quarter earnings surprise of 10.06%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have decreased 0.7%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 64 cents. In the past year, shares of PBYI have lost 4.1%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.